MA51620A - Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques - Google Patents
Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaquesInfo
- Publication number
- MA51620A MA51620A MA051620A MA51620A MA51620A MA 51620 A MA51620 A MA 51620A MA 051620 A MA051620 A MA 051620A MA 51620 A MA51620 A MA 51620A MA 51620 A MA51620 A MA 51620A
- Authority
- MA
- Morocco
- Prior art keywords
- dihydrobenzofurane
- inden
- sarcomas
- analogues
- cardiac
- Prior art date
Links
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 title 1
- 206010039491 Sarcoma Diseases 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619643P | 2018-01-19 | 2018-01-19 | |
| US201862745724P | 2018-10-15 | 2018-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51620A true MA51620A (fr) | 2020-11-25 |
Family
ID=65324663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051620A MA51620A (fr) | 2018-01-19 | 2019-01-18 | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10836755B2 (fr) |
| EP (1) | EP3740481B1 (fr) |
| JP (2) | JP7401439B2 (fr) |
| KR (1) | KR20200112895A (fr) |
| CN (3) | CN111757875B (fr) |
| AU (1) | AU2019208331B2 (fr) |
| BR (1) | BR112020014428A2 (fr) |
| CA (1) | CA3087283A1 (fr) |
| CL (2) | CL2020001871A1 (fr) |
| CO (1) | CO2020009225A2 (fr) |
| DK (1) | DK3740481T3 (fr) |
| EC (1) | ECSP20044709A (fr) |
| IL (1) | IL276094B2 (fr) |
| MA (1) | MA51620A (fr) |
| MX (2) | MX2020007532A (fr) |
| PH (1) | PH12020551090A1 (fr) |
| SG (1) | SG11202006296YA (fr) |
| TW (1) | TWI835770B (fr) |
| UY (1) | UY38057A (fr) |
| WO (1) | WO2019144041A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10836755B2 (en) | 2018-01-19 | 2020-11-17 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP3814343B1 (fr) * | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Inhibiteurs de sarcomères cardiaques |
| JP7438148B2 (ja) * | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| JP2022530989A (ja) * | 2019-05-03 | 2022-07-05 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤および使用する方法 |
| CA3144974A1 (fr) * | 2019-07-17 | 2021-01-21 | Norma TOM | Polymorphes de (r)-n-(5-(5-isopropyl -1,2,4-oxadiazol-3-yl)-2,3-dihydro-1 h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide |
| DK3999180T3 (da) * | 2019-07-17 | 2024-05-21 | Cytokinetics Inc | Polymorfer af (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1 -methyl-1H-pyrazol-4-carboxamid |
| ES2974542T3 (es) | 2019-07-17 | 2024-06-27 | Cytokinetics Inc | Formulaciones orales de inhibidores del sarcómero cardíaco |
| CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
| AR125026A1 (es) | 2021-03-04 | 2023-05-31 | Cytokinetics Inc | Inhibidores del sarcómero cardíaco |
| AU2022312506A1 (en) | 2021-07-16 | 2024-02-01 | Cytokinetics, Inc. | Methods for treating hypertrophic cardiomyopathy |
| TW202315619A (zh) | 2021-08-03 | 2023-04-16 | 美商胞質動力學公司 | 用於製備阿非卡坦(aficamten)之方法 |
| US20230338378A1 (en) | 2022-04-26 | 2023-10-26 | MyoKardia, Inc. | Methods of Administering Myosin Inhibitors |
| US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| WO2024031016A1 (fr) | 2022-08-04 | 2024-02-08 | Cytokinetics, Incorporated | Méthodes de traitement de la cardiomyopathie hypertrophique obstructive |
| WO2024040190A1 (fr) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Dérivés d'indane et de coumarane utilisés en tant qu'inhibiteurs de myosine du muscle squelettique rapide |
| WO2024134498A1 (fr) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Formes à l'état solide d'aficamten et leur procédé de préparation |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633499A (en) | 1899-06-29 | 1899-09-19 | Oil Well Supply Co | Coupling for pipes, tubes, or casings. |
| WO1995026325A2 (fr) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| MXPA05007513A (es) * | 2003-01-14 | 2005-09-21 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
| EP1605752B1 (fr) | 2003-03-27 | 2011-09-14 | Cytokinetics, Inc. | Sulfonamides pour le traitment de l' insuffisance cardiaque congestive, leur compositions et utilisations. |
| RU2006101541A (ru) * | 2003-06-20 | 2006-06-10 | Амген Инк. (US) | Производные пиперазина и способ их применения |
| ES2686357T3 (es) * | 2004-06-17 | 2018-10-17 | Cytokinetics, Inc. | Compuestos, composiciones y procedimientos |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CA2604916A1 (fr) | 2005-04-22 | 2006-11-02 | Wyeth | Derives de dihydrobenzofurane et utilisations associees |
| US7718657B2 (en) * | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| US20110275673A1 (en) * | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| MA33358B1 (fr) | 2009-05-15 | 2012-06-01 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
| US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| JP6111268B2 (ja) | 2012-01-20 | 2017-04-05 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| WO2014205234A1 (fr) | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Composés de pyrimidinedione substitués par cycloalkyle |
| MY190860A (en) | 2013-06-21 | 2022-05-12 | Myokardia Inc | Pyrimidinedione compounds against cardiac conditions |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| FI3247707T3 (fi) | 2015-01-22 | 2023-08-22 | Myokardia Inc | Sydänhäiriöiden kuten dilatoivan kardiomyopatian (dcm) hoitoon hyödyllisiä 4-metyylisulfonyylisubstituoituja piperidiiniureayhdisteitä |
| JP2019507110A (ja) | 2015-12-17 | 2019-03-14 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物性オキサジアゾール誘導体 |
| US20190364899A1 (en) | 2015-12-18 | 2019-12-05 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| EP3448519A4 (fr) | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | Liants de récepteur sigma |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| CA3037537C (fr) | 2016-09-27 | 2021-06-15 | Merck Sharp & Dohme Corp. | Derives de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allosteriques negatifs de mglur2, compositions et leur utilisation |
| WO2018089433A1 (fr) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | Inhibiteurs de mtorc phényle et leurs utilisations |
| US20200000822A1 (en) | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| AU2018311974B2 (en) | 2017-08-04 | 2024-03-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| US10836755B2 (en) | 2018-01-19 | 2020-11-17 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP3762368B1 (fr) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
| EP3814343B1 (fr) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Inhibiteurs de sarcomères cardiaques |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
-
2019
- 2019-01-18 US US16/252,483 patent/US10836755B2/en active Active
- 2019-01-18 UY UY38057A patent/UY38057A/es unknown
- 2019-01-18 BR BR112020014428-2A patent/BR112020014428A2/pt unknown
- 2019-01-18 CN CN201980009128.5A patent/CN111757875B/zh active Active
- 2019-01-18 CN CN202311746655.9A patent/CN117964573A/zh active Pending
- 2019-01-18 EP EP19703917.5A patent/EP3740481B1/fr active Active
- 2019-01-18 JP JP2020539814A patent/JP7401439B2/ja active Active
- 2019-01-18 TW TW108101933A patent/TWI835770B/zh active
- 2019-01-18 KR KR1020207023807A patent/KR20200112895A/ko not_active Application Discontinuation
- 2019-01-18 SG SG11202006296YA patent/SG11202006296YA/en unknown
- 2019-01-18 CN CN202311746636.6A patent/CN117924208A/zh active Pending
- 2019-01-18 MX MX2020007532A patent/MX2020007532A/es unknown
- 2019-01-18 AU AU2019208331A patent/AU2019208331B2/en active Active
- 2019-01-18 CA CA3087283A patent/CA3087283A1/fr active Pending
- 2019-01-18 WO PCT/US2019/014344 patent/WO2019144041A1/fr unknown
- 2019-01-18 MA MA051620A patent/MA51620A/fr unknown
- 2019-01-18 DK DK19703917.5T patent/DK3740481T3/da active
-
2020
- 2020-07-14 MX MX2022014312A patent/MX2022014312A/es unknown
- 2020-07-14 CL CL2020001871A patent/CL2020001871A1/es unknown
- 2020-07-16 IL IL276094A patent/IL276094B2/en unknown
- 2020-07-16 PH PH12020551090A patent/PH12020551090A1/en unknown
- 2020-07-27 CO CONC2020/0009225A patent/CO2020009225A2/es unknown
- 2020-07-31 EC ECSENADI202044709A patent/ECSP20044709A/es unknown
- 2020-09-04 US US17/013,472 patent/US11472796B2/en active Active
-
2022
- 2022-04-28 CL CL2022001091A patent/CL2022001091A1/es unknown
- 2022-08-31 US US17/823,910 patent/US20230119665A1/en active Pending
-
2023
- 2023-09-26 JP JP2023163639A patent/JP2023169374A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51620A (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA44991A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA46180A (fr) | Analogues de l'amyline | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA53491A (fr) | Inhibiteurs de sarcomes cardiaques | |
| MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
| MA50013A (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
| IT201900020514A1 (it) | Dispositivo di irrigazione e/o fertirrigazione | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| UA42366S (uk) | Комплект етикеток | |
| UA42073S (uk) | Комплект етикеток | |
| UA41330S (uk) | Комплект етикеток | |
| UA40681S (uk) | Комплект етикеток | |
| UA41684S (uk) | Комплект етикеток | |
| UA40980S (uk) | Комплект етикеток | |
| UA40316S (uk) | Комплект етикеток |